DCGI grants Emergency Use Authorization to Gennova biopharma's Omicron-specific covid booster

The mRNA-based vaccine was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UDJqf6u
via IFTTT